JP2005510491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510491A5 JP2005510491A5 JP2003537573A JP2003537573A JP2005510491A5 JP 2005510491 A5 JP2005510491 A5 JP 2005510491A5 JP 2003537573 A JP2003537573 A JP 2003537573A JP 2003537573 A JP2003537573 A JP 2003537573A JP 2005510491 A5 JP2005510491 A5 JP 2005510491A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antigen
- formulated
- composition according
- ncm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 230000003902 lesion Effects 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 208000024550 neurocutaneous melanocytosis Diseases 0.000 claims 9
- 238000002347 injection Methods 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 6
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 6
- 210000001165 lymph node Anatomy 0.000 claims 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000002085 persistent effect Effects 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 3
- 108090001005 Interleukin-6 Proteins 0.000 claims 3
- 108090001007 Interleukin-8 Proteins 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 230000036039 immunity Effects 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 239000012645 endogenous antigen Substances 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 206010025327 Lymphopenia Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000004308 accommodation Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- -1 biox Chemical compound 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940047495 celebrex Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 231100001023 lymphopenia Toxicity 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34450901P | 2001-10-26 | 2001-10-26 | |
| PCT/US2002/034361 WO2003035004A2 (en) | 2001-10-26 | 2002-10-26 | Immunotherapy for reversing immune suppression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009139689A Division JP2009197032A (ja) | 2001-10-26 | 2009-06-10 | 免疫抑制を逆転させるための免疫治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510491A JP2005510491A (ja) | 2005-04-21 |
| JP2005510491A5 true JP2005510491A5 (cg-RX-API-DMAC7.html) | 2006-01-05 |
Family
ID=23350824
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003537573A Pending JP2005510491A (ja) | 2001-10-26 | 2002-10-26 | 免疫抑制を逆転させるための免疫治療 |
| JP2009139689A Pending JP2009197032A (ja) | 2001-10-26 | 2009-06-10 | 免疫抑制を逆転させるための免疫治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009139689A Pending JP2009197032A (ja) | 2001-10-26 | 2009-06-10 | 免疫抑制を逆転させるための免疫治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7731945B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1446159A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2005510491A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002342151B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2498591A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04003864A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003035004A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
| US7182942B2 (en) | 2000-10-27 | 2007-02-27 | Irx Therapeutics, Inc. | Vaccine immunotherapy for immune suppressed patients |
| EP1337149A4 (en) | 2000-10-27 | 2005-10-12 | Irx Therapeutics Inc | VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS |
| CA2498591A1 (en) | 2001-10-26 | 2003-05-01 | Immuno-Rx, Inc. | Immunotherapy for reversing immune suppression |
| US6896879B2 (en) * | 2003-07-03 | 2005-05-24 | Cel-Sci Corporation | Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| WO2005037995A2 (en) * | 2003-10-06 | 2005-04-28 | Cedars-Sinai Medical Center | Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy |
| EP1676132B1 (en) | 2003-10-21 | 2014-01-22 | Cedars-Sinai Medical Center | Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma |
| BRPI0518571A2 (pt) * | 2004-12-06 | 2008-11-25 | Sciclone Pharmaceuticals Inc | peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer |
| EP2084267B1 (en) | 2006-09-26 | 2018-04-11 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| WO2008039969A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| AU2008329741B2 (en) * | 2007-11-28 | 2013-09-12 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
| RU2385875C2 (ru) * | 2008-04-24 | 2010-04-10 | Ибмед Холдингс Лимитед | Пептид, обладающий ростостимулирующей активностью гранулоцитарного колониестимулирующего фактора человека |
| RU2374262C1 (ru) * | 2008-05-22 | 2009-11-27 | Ибмед Холдингс Лимитед | Олигопептид, обладающий активностью фактора стволовых клеток csf по отношению к дифференцировке тимоцитов |
| US9068020B2 (en) | 2008-09-02 | 2015-06-30 | Cedars-Sinai Medical Center | CD133 epitopes |
| US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| DK2427485T3 (en) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | CD133 epitopes |
| JP2012526149A (ja) * | 2009-05-08 | 2012-10-25 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | ワクチン増強剤としてのαチモシンペプチド |
| EP2429585B1 (en) | 2009-05-15 | 2018-04-18 | IRX Therapeutics, Inc. | Vaccine immunotherapy |
| JP5889797B2 (ja) | 2009-12-08 | 2016-03-22 | アイアールエックス セラピューティクス， インコーポレイテッド | ランゲルハンス細胞の免疫抑制を逆転させる方法 |
| WO2013136182A1 (en) * | 2012-03-15 | 2013-09-19 | Macrocure, Ltd. | Activated immunostimulatory cell composition and uses thereof |
| EP2909324B1 (en) | 2012-10-25 | 2020-02-26 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
| ES2662333T3 (es) | 2013-02-14 | 2018-04-06 | Immunocellular Therapeutics Ltd. | Vacunas contra el cáncer y métodos de vacunación |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4116951A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | [Asn2 ]-thymosin α1 and analogs thereof |
| DE2919592A1 (de) * | 1979-05-15 | 1981-01-15 | Max Planck Gesellschaft | Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon |
| US4470926A (en) * | 1980-01-18 | 1984-09-11 | Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. | Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1 |
| DE3100974A1 (de) * | 1980-01-18 | 1982-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente |
| US4612365A (en) * | 1980-03-25 | 1986-09-16 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften | Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments |
| US4390623A (en) * | 1980-10-02 | 1983-06-28 | Hooper Trading Company | Serum-free and mitogen-free T-cell growth factor and process for making same |
| US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4464355A (en) | 1981-03-26 | 1984-08-07 | Hooper Trading Co. | Serum-free and mitogen-free T-cell growth factor and process for making same |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| DE3120912A1 (de) * | 1981-05-26 | 1982-12-16 | Hoechst Ag, 6000 Frankfurt | Verfahren zur herstellung von p-nitrophenetol |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US5100664A (en) * | 1985-09-20 | 1992-03-31 | Cetus Corporation | Human IL-2 as a vaccine adjuvant |
| US5643565A (en) * | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
| US5503841A (en) * | 1985-09-20 | 1996-04-02 | Cetus Oncology Corporation | Human IL-2 as a vaccine adjuvant |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) * | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5167616A (en) * | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| US5354580A (en) * | 1993-06-08 | 1994-10-11 | Cvd Incorporated | Triangular deposition chamber for a vapor deposition system |
| US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| ES2236719T3 (es) * | 1994-11-17 | 2005-07-16 | University Of South Florida | Metodo para fabricar un medicamento para el tratamiento de la inmunodeficiencia secundaria. |
| GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| EP0974357A1 (en) * | 1998-07-16 | 2000-01-26 | Schering-Plough | Chemokines as adjuvants of immune response |
| IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| EP1337149A4 (en) * | 2000-10-27 | 2005-10-12 | Irx Therapeutics Inc | VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS |
| CA2498591A1 (en) | 2001-10-26 | 2003-05-01 | Immuno-Rx, Inc. | Immunotherapy for reversing immune suppression |
-
2002
- 2002-10-26 CA CA002498591A patent/CA2498591A1/en not_active Abandoned
- 2002-10-26 WO PCT/US2002/034361 patent/WO2003035004A2/en not_active Ceased
- 2002-10-26 JP JP2003537573A patent/JP2005510491A/ja active Pending
- 2002-10-26 AU AU2002342151A patent/AU2002342151B2/en not_active Expired
- 2002-10-26 US US10/280,627 patent/US7731945B2/en not_active Expired - Lifetime
- 2002-10-26 MX MXPA04003864A patent/MXPA04003864A/es active IP Right Grant
- 2002-10-26 EP EP02776317A patent/EP1446159A4/en not_active Ceased
- 2002-10-26 EP EP07007974A patent/EP1810691A3/en not_active Ceased
-
2009
- 2009-06-10 JP JP2009139689A patent/JP2009197032A/ja active Pending
-
2010
- 2010-03-29 US US12/748,622 patent/US20110044941A1/en not_active Abandoned
-
2012
- 2012-10-16 US US13/653,152 patent/US20130164255A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510491A5 (cg-RX-API-DMAC7.html) | ||
| US8784796B2 (en) | Vaccine immunotherapy for treating hepatocellular cancer in immune suppressed patients | |
| JP2004521867A5 (cg-RX-API-DMAC7.html) | ||
| US20110044941A1 (en) | Immunotherapy for reversing immune suppression | |
| AU2002342151A1 (en) | Immunotherapy for reversing immune suppression | |
| CN1355709A (zh) | 肿瘤疫苗 | |
| JP4371437B2 (ja) | 悪性腫瘍の治療方法 | |
| Gattinoni et al. | Renal cancer treatment: a review of the literature | |
| Bear et al. | Biologic therapy of melanoma with cytokines and lymphocytes | |
| Krosnick et al. | Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice | |
| Barnavon et al. | Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2 | |
| Gough | Overview: Exploitation of the Contrasting Immunomodulatory Characteristics of Interleukin-2-A Review and Comment on Recent Patent Literature | |
| HK1107267A (en) | Immunotherapy for reversing immune suppression |